Status:
COMPLETED
Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
GC Biopharma Corp
Conditions:
Malignant Lymphomas
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and exp...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Histologically or cytologically confirmed malignant lymphoma or solid tumor
- After the failure of standard treatment
- KPS \>70 or ECOG PS 0-2
- Adequate bone marrow, renal, and liver functions
- Expected survival at least 3 months
- Informed consent
Exclusion
- Pregnancy or lactating woman
- HIV patients
- Prior exposure to cell-based therapy
- Hypersensitivity to interleukin-2
- Patients with autoimmune disease
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2013
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01212341
Start Date
September 1 2010
End Date
March 1 2013
Last Update
August 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744